Weekly Brief · 3. Juni 2026
Studies, policy and care. Gathered automatically, curated by Radiosa.
This article is for information purposes and does not replace medical advice.
The bright pink container is touring ten cantons that have no mammography screening. Four-year tally: 1,650 exams, 5 confirmed cancer diagnoses. Next stops: Sarnen on June 12, Stans on June 19.
Learn moreThis article is for information purposes and does not replace medical advice.
A 55 to 0 vote, with a 1.28 million franc budget. Launch in Q4 2026 or early 2027. Schaffhausen closes the last big gap in screening coverage in German-speaking Switzerland.
This article is for information purposes and does not replace medical advice.
A 12-gene test on tumor tissue shows who really needs chemotherapy alongside hormone therapy. For two out of three patients, chemo turned out to be unnecessary, with no drop in their chances of recovery. Included for the first time: patients with four or more affected lymph nodes.
This article is for information purposes and does not replace medical advice.
Resistant breast cancer cells develop a metabolic vulnerability. Drugs like metformin could tap into this energy stress and trigger cell death. This affects 70% of all breast cancer subtypes.
This article is for information purposes and does not replace medical advice.
In May 2026, LILT in Taranto offered free screenings for women with a low ISEE score. Age groups 39 to 49 and 69 to 75. Relevant to Radiosa's community work with the Italian-speaking population in Switzerland.
This article is for information purposes and does not replace medical advice.
Mediterranean and plant-based diets came out on top. A healthy body weight could prevent around 13,000 cases a year.
This article is for information purposes and does not replace medical advice.
In May, SGS, SGR-SSR, and SGGG jointly recommended inviting women to mammography starting at age 45. For women between 40 and 49, breast cancer is already the second most common cause of death. International data show up to 25% lower mortality with earlier screening.
This article is for information purposes and does not replace medical advice.
A phase 3 study at ASCO 2026: switching to camizestrant right when an ESR1 mutation shows up in a blood test, instead of waiting for clinical relapse, cuts the risk of progression by 55%. Median PFS: 16 versus 9.2 months. ctDNA monitoring as a guide for treatment decisions.
This article is for information purposes and does not replace medical advice.
Mortality from tumore al seno in Italy has dropped 6% over five years. Early detection and treatment advances are paying off. But the decline isn't reaching every region equally, and the South in particular is lagging behind. Relevant to Radiosa and the Italian-speaking community in Switzerland.
This article is for information purposes and does not replace medical advice.
The Istituto Pascale presented data at ASCO 2026: women with breast cancer who followed a structured program of a Mediterranean diet, daily exercise, and vitamin D supplements had far fewer metastases and recurrences. The effect was especially strong in younger patients.
This article is for information purposes and does not replace medical advice.